Physician profile
Stephen J Smart
NPI 1265429625
$41,263.79
in general payments reported to CMS, 2019-2025
38 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,969 · 2020: $1,294 · 2021: $1,455 · 2022: $19K · 2023: $11K · 2024: $1,781 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,350 · Food and Beverage: $5,942 · Education: $162 · Travel and Lodging: $130 · Consulting Fee: $24.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,350.00 |
| Food and Beverage | $5,942.34 |
| Education | $162.18 |
| Travel and Lodging | $129.95 |
| Consulting Fee | $24.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,427.41 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,227.38 | 2019-2023 | Spiriva Respimat |
| Glaxosmithkline, LLC. | $1,709.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,074.97 | 2020-2025 | Cuvitru, Eohilia, Takhzyro |
| Genzyme Corporation | $1,032.21 | 2019-2025 | |
| Csl Behring | $898.74 | 2019-2025 | Hizentra |
| Regeneron Healthcare Solutions, INC. | $857.02 | 2020-2025 | Dupixent |
| Pfizer INC. | $545.82 | 2019-2025 | |
| Genentech USA, INC. | $333.60 | 2019-2025 | Xolair |
| Grifols USA, LLC | $333.06 | 2019-2024 | Xembify |
| Novartis Pharmaceuticals Corporation | $315.08 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $293.49 | 2019-2023 | Airduo Digihaler |
| Optinose US, INC. | $280.96 | 2020-2025 | |
| Ars Pharmaceuticals Operations, INC. | $187.94 | 2025 | Neffy |
| Horizon Therapeutics Plc | $178.81 | 2019-2023 | Actimmune |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.